Stockscreener 앱 받기
0.676
3.57%
-0.025
시간 외 거래:
.68
0.004
+0.59%
전일 마감가:
$0.701
열려 있는:
$0.71
하루 거래량:
3.36M
Relative Volume:
1.83
시가총액:
$123.99M
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-0.463
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
-18.29%
1개월 성능:
-43.19%
6개월 성능:
-42.71%
1년 성능:
+0.90%
1일 변동 폭
$0.6618
$0.72
1주일 범위
$0.6618
$0.8565
52주 변동 폭
$0.6303
$1.928
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
0.676 | 123.99M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Nektar Therapeutics (NKTR) Stock Drops Amid Biotech Sector Volat - GuruFocus.com
Chutes & Ladders—J&J vet jumps to Affinia - Fierce Biotech
Nektar Therapeutics Sees Unusually High Options Volume (NASDAQ:NKTR) - MarketBeat
Nektar Therapeutics announces senior leadership change - MSN
Nektar Names Kotzin Interim Chief Medical Officer - MarketWatch
Metastatic Melanoma Pipeline 2024: MOA and ROA Insights, - openPR
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Shares Purchased by HB Wealth Management LLC - Defense World
B. Riley Securities Initiates Coverage of Nektar Therapeutics (NKTR) with Buy Recommendation - MSN
JPMorgan Chase & Co. Buys 606,057 Shares of Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
JPMorgan Chase & Co. Grows Position in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Nurix Therapeutics Taps Former Ibrutinib Commercial Chief to Lead NX-5948 Launch Strategy - StockTitan
Barclays PLC Purchases 175,596 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Phase 2b study of rezpegaldesleukin for atopic dermatitis reaches target enrollment - Healio
Analysts Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $4.08 - Defense World
B-Cell Lymphoma Clinical and Non-Clinical Studies, Key - openPR
Nektar Therapeutics (NASDAQ:NKTR) Stake Lifted by Jane Street Group LLC - Defense World
LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times
Nektar Therapeutics (NASDAQ:NKTR) Receives "Buy" Rating from HC Wainwright - MarketBeat
Analysts Issue Forecasts for NKTR FY2024 Earnings - Defense World
Nektar hits enrollment target for atopic dermatitis study By Investing.com - Investing.com Australia
Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin - Dermatology Times
Nektar hits enrollment target for atopic dermatitis study - Investing.com India
Nektar Therapeutics (NKTR) competes target enrollment in its REZOLVE-AD Phase 2b study - StreetInsider.com
Nektar's Key Atopic Dermatitis Drug Trial Hits Full Enrollment Ahead of Schedule - StockTitan
Nektar Therapeutics to sell Alabama facility to Ampersand - MSN
B. Riley Upgrades Nektar Therapeutics (NASDAQ:NKTR) to Strong-Buy - MarketBeat
Nektar stock positioned for growth as B. Riley forecasts REZPEG as key AD market disruptor By Investing.com - Investing.com South Africa
Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at B. Riley - MarketBeat
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Nektar stock positioned for growth as B. Riley forecasts REZPEG as key AD market disruptor - Investing.com India
B.Riley Starts Nektar Therapeutics (NKTR) at Buy - StreetInsider.com
Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance
12 Best Penny Stocks to Invest in According to the Media - Insider Monkey
Numerous Nektar Therapeutics Insiders Sold Stock: Not A Positive Omen - Simply Wall St
Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership - Yahoo Finance
Nektar Therapeutics chief legal officer sells shares worth $44,800 By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 33,402 Shares - MarketBeat
Nektar Therapeutics chief legal officer sells shares worth $44,800 - Investing.com
Why Nektar Therapeutics May Be About to Take Off - AOL
Nektar Therapeutics chief R&D officer sells $48,048 in stock By Investing.com - Investing.com Australia
Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $48,048.10 in Stock - MarketBeat
Nektar Therapeutics chief R&D officer sells $48,048 in stock - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Howard W. Robin Sells 46,995 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
Nektar Therapeutics CEO Robin Howard sells $131,649 in stock By Investing.com - Investing.com Australia
Nektar Therapeutics CEO Robin Howard sells $131,649 in stock - Investing.com India
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
넥타테라퓨틱스 주식 (NKTR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | Chief Legal Officer |
Dec 24 '24 |
Sale |
0.89 |
16,560 |
14,738 |
335,332 |
1.09%
자본화:
|
볼륨(24시간):